Metadata
- Name
- Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer
- Repository
- ClinicalTrials.gov
- Identifier
- clinicaltrials:NCT04190667
- Description
- The homologous recombination deficiency (HRD) status in Chinese population with epithelial
ovarian cancer (EOC) is little known. This study would recruit 1300 Chinese EOC patients. A
multi-panel testing of 36 genes would be given for these patients in their peripheral blood
and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A?, ATM, ATR, BAP1,
BARD1, BRIP1, C11ORF30?EMSY?, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL,
MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2,
MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or
likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further
explore the HRD status. The HRD model is based on the loss of heterozygosity (LOH), telomere
allele imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score
model and their relationship with the prognosis, would provide a full description of for the
Chinese EOC patients. - Data or Study Types
- clinical trial
- Source Organization
- Unknown
- Access Conditions
- available
- Year
- 2019
- Access Hyperlink
- https://clinicaltrials.gov/ct2/show/NCT04190667
Distributions
- Encoding Format: HTML ; URL: https://clinicaltrials.gov/ct2/show/results/NCT04190667